New screening could open door to T-Cell therapy for Hard-to-Treat cancers

NCT ID NCT05812027

Ongoing Knowledge-focused Sponsor: TScan Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit from these experimental treatments, but no therapy is given in this study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this screening could help identify patients who may benefit from future T-cell therapies for solid tumors.
What could go wrong: This is only a screening study, not a treatment. It does not test any therapy, so there is no direct benefit to participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma carcinoma cervical cancer head and neck cancer Head and Neck Neoplasms human papillomavirus-related squamous cell carcinoma non-small cell lung carcinoma nut midline carcinoma sarcoma squamous cell carcinoma Uterine Cervical Neoplasms uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER HEAD AND NECK CANCER HPV16 RELATED CANCERS NON-SMALL CELL LUNG CANCER NUT CARCINOMA SARCOMA UVEAL MELANOMA

Contacts and locations

Locations

Allegheny Hospitals Network

Pittsburgh, Pennsylvania, 15224, United States
Baylor College of Medicine

Houston, Texas, 77030, United States
Columbia University Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
HonorHealth Research and Innovation Institute

Scottsdale, Arizona, 85258, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Memorial Healthcare System

Hollywood, Florida, 33021, United States
Norton Cancer Institute

Louisville, Kentucky, 40202, United States
OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
Oncology Hematology Care

Cincinnati, Ohio, 45242, United States
Orlando Health

Orlando, Florida, 32806, United States
Providence Cancer Institute Franz Clinic

Portland, Oregon, 97213, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
The Cleveland Clinic

Cleveland, Ohio, 44195, United States
University of California San Diego

San Diego, California, 92037, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Miami, Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
University of Minnesota, Masonic Cancer Center

Minneapolis, Minnesota, 55455, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
University of South Florida

Tampa, Florida, 33606, United States
Yale Cancer Center

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.